Windtree Therapeutics, Inc. Common Stock
WINT Real Time Price USDRecent trades of WINT by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by WINT's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
WINT Revenue by Segment or Geography
New patents grants
-
Patent Title: Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf) Feb. 21, 2023
-
Patent Title: Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf) Dec. 14, 2021
-
Patent Title: Ventilation circuit adaptor and proximal aerosol delivery system Mar. 14, 2017
-
Patent Title: Lyophilization of synthetic liposomal pulmonary surfactant Jan. 31, 2017
-
Patent Title: Ventilation circuit adaptor and proximal aerosol delivery system May. 31, 2016
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to WINT
Recent picks made for WINT stock on CNBC
ETFs with the largest estimated holdings in WINT
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $WINT stock a Buy, Sell, or Hold?
- What is the price target for $WINT stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $WINT stock?
- Who owns the most shares of $WINT stock?
- What funds own $WINT stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view WINT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.